Abbott Laboratories (ABT) FY2015 results: revenue $20.4 billion, up 0.8% on the year
Abbott Laboratories (ABT) reported revenue of $20.4 billion for fiscal 2015, the year ended 31 December 2015, up 0.8% on the year before. Net income was $4.4 billion, up 93.7%, and diluted earnings per share $2.92. The figures are the company's own, from the 10-K it filed with the SEC on 19 February 2016.
Revenue
$20.4 billion
+0.8% on the year
FY2008FY2015
Operating margin
14.1%
12.8% a year earlier
FY2008FY2015
Net income
$4.4 billion
+93.7% on the year
FY2008FY2015
Diluted EPS
$2.92
+96.0% on the year
FY2008FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
20,405
20,247
19,657
+0.8%
Cost of revenue
8,747
9,218
9,193
-5.1%
Gross profit
11,658
11,029
10,464
+5.7%
Gross margin
57.1%
54.5%
53.2%
Research and development
1,405
1,345
1,371
+4.5%
Selling, general and administrative
6,785
6,530
6,372
+3.9%
Operating income
2,867
2,599
2,133
+10.3%
Operating margin
14.1%
12.8%
10.9%
Interest expense
163
150
145
+8.7%
Pre-tax income
3,183
2,518
2,041
+26.4%
Income tax
577
797
53.0
-27.6%
Effective tax rate
18.1%
31.7%
2.6%
Net income
4,423
2,284
2,576
+93.7%
Net margin
21.7%
11.3%
13.1%
Diluted EPS
$2.92
$1.49
$1.62
+96.0%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
2,966
3,675
3,324
-19.3%
Capital expenditure
1,110
1,077
1,145
+3.1%
Free cash flow
1,856
2,598
2,179
-28.6%
Free cash flow margin
9.1%
12.8%
11.1%
Cash from investing
406
-202
-3,929
Cash from financing
-2,236
-2,742
-6,696
Depreciation and amortisation
1,472
1,548
1,719
-4.9%
Share-based compensation
292
246
262
+18.7%
Buybacks
2,237
2,195
1,605
+1.9%
Dividends paid
1,443
1,342
882
+7.5%
Diluted shares, weighted
1,506m
1,527m
1,574m
-1.4%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
21,211
21,526
25,171
-1.5%
Non-controlling interest
115
113
96.0
+1.8%
Debt
9,001
7,830
6,561
+15.0%
Other liabilities
10,920
11,806
11,125
-7.5%
Total liabilities and equity
41,247
41,275
42,953
-0.1%
Fixed assets
5,730
5,935
5,905
-3.5%
Goodwill
9,638
10,067
9,772
-4.3%
Intangible assets
5,562
6,198
5,735
-10.3%
Investments
5,165
626
4,742
+725.1%
Cash and equivalents
5,001
4,063
3,475
+23.1%
Receivables
3,418
3,586
3,986
-4.7%
Inventory
2,599
2,643
2,693
-1.7%
Other assets
4,134
8,157
6,645
-49.3%
Total assets
41,247
41,275
42,953
-0.1%
10-K for the year ended 31 December 2015, filed 19 February 2016: the filing.